Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC50 of 50 μM.

CP 376395 is a potent and selective CRF1 receptor antagonist (Ki values are 12 and >10000 nM for CRF1 and CRF2 receptors respectively).

CP 673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.

CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM.

CP21R7 is a potent and selective GSK-3β inhibitor.

CP-31398 is a small molecule p53 reactivator that protects p53 from thermal denaturation, not only reactivates mutant p53 but also induces stabilization of wild type p53.

CP-339818 is a potent, selective, non-peptide KV1.3 channel antagonist with IC50 of 200 nM.

CP-466722 is an potent and reversible ATM inhibitor.

CP-544326 is a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.

CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively).

CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.

CP-640186 is an isozyme-nonselective acetyl-CoA carboxylase inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively.

CP-671305 is a potent and selective inhibitor of phosphodiesterase 4.

CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance.

CPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay.

CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex.

CPI-169 R is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2.

CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apo

CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay).

CPI-268456 is a potential BET bromodomain inhibitor.

CPI-360 is a compound in design and preparation of wew palladium precatalysts for C-C and C-N cross-coupling reactions.

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.